Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19/20/22 CAR T-Cells for Relapsed or Refractory Lymphoid Malignancies
NCT05418088Phase 1Recruiting
- Start
- Jun 2022
- Primary completion
- Jul 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of TriCAR19.20.22 T cells in non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and 1 more (3 cohorts). Primary endpoint: Recommended Phase II Dose at 30 days. Started Jun 2022; status: recruiting.
02
Drugs
TriCAR19.20.22 T cells
03
Conditions
non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)B-cell prolymphocytic leukemia (B-PLL)
Beyond the preview
Go deeper on NCT05418088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418088.